NMDP Donor for All initiative

Increasing the odds for all patients

Our NMDPSM Donor for All initiative includes many research efforts that aim to establish a new safe and effective approach for using mismatched unrelated donor (MMUD) transplants in the U.S. and abroad.

This will significantly increase the odds that patients with diverse ancestry will find a suitably matched, available donor on the NMDP RegistrySM—all while providing equal outcomes comparable to current survival rates with an 8/8 matched donor. Explore the work that's increasing the odds your patient will find a life-saving match.

Then connect with an NMDP clinical operations partner in your region to discuss the Donor for All initiative and how you can get involved.

A smiling man and woman share a warm hug, looking directly at the camera.
Transplant recipient, Noe, with his donor, Trish
Dr. Al Malki

By demonstrating that mismatched unrelated donors can be used safely and effectively, we are opening the door to curative therapy for patients who historically had limited or no donor options."

Monzr M. Al Malki, MD

ACCESS Study Co-Chair | Associate Professor, Department of Hematology & 
Hematopoietic Cell Transplantation, City of Hope

Donor for All initiative clinical trials

NMDP is sponsoring a series of Phase II clinical trials conducted by CIBMTR® (Center for International Blood and Marrow Transplant Research®) studying the use of post-transplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis in MMUD HCT (patients matched at 4/8 to 7/8 alleles). CIBMTR is a research collaboration between the Medical College of Wisconsin® and NMDP.

The clinical trials are designed to be as inclusive as possible. For those clinical trials that have completed enrollment, more than 50% of patients enrolled have diverse ancestries. Historical enrollment in HCT clinical trials has been less than 20% ethnically diverse ancestry.

Donor for All initiative observational studies

Observational studies through CIBMTR indicate the use of MMUDs will truly make a difference in equalizing outcomes and expanding access for patients.

PTCy equalizes MUD and MMUD HCT outcomes

Research from CIBMTR published in the Journal of Clinical Oncology shows that with PTCy, the outcomes between 8/8 matched and 7/8 matched unrelated donor transplant are equivalent. They found no significant differences in overall survival (OS) or GVHD-free, relapse-free survival (GRFS) between the two groups.
Review the study (Opens in a new tab)

MMUDs expand access for nearly 100% of patients

CIBMTR found that allowing for a 5/8 HLA match level could bridge the donor availability gap for those with diverse ancestry. Using a 5/8 match level increased the NMDP Registry coverage to greater than 99% for all groups even when considering only donors who are 35 years old and younger.
Review the study

Articles and news

NMDP is dedicated to spreading the word that MMUD HCT is proving to be safe and effective and encouraging practice change at hematology/oncology practices, transplant centers and international registries.

Evolution of HCT to overcome access disparities

In this paper published in Cells, NMDP Chief Medical Officer and CIBMTR Senior Scientific Director Steven Devine, MD, explores the recent work of NMDP to address access gaps in HCT by improving MMUD outcomes. He shares the evolution of matched and mismatched unrelated HCT over the years.

Read the paper (Opens in a new tab)

Breaking HLA-related barriers in alloHCT

In this article published in The Hematologist, NMDP Chief Medical Officer and CIBMTR Senior Scientific Director Steven Devine, MD, explores MMUD HCT research, including how PTCy and the FDA-approved abatacept for acute GVHD prevention are shifting the treatment paradigm.

Read the article (Opens in a new tab)

PTCy offers new hope for MMUD HCT

In an interview with Targeted Oncology, Jeff Auletta, MD, discusses how PTCy is offering a promising approach for expanding HCT access regardless of match level or a patient's ethnicity. Dr. Auletta is the chief scientific director for CIBMTR-NMDP and senior vice president of CIBMTR and Clinical Services for NMDP.

Read the interview (Opens in a new tab)

Contact our team

Questions about the Donor for All initiative, MMUD clinical trials or how you can get involved? Talk to your NMDP clinical operations partner or fill out the form and a clinical operations partner in your region will connect with you.